Congress Materials – Maui Derm Hawaii 2025
2025 Maui Derm Hawaii | Jan 20-24 | Maui, HI
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
On-Label Persistence in Psoriasis After Switching to Guselkumab or Interleukin 17A Inhibitors from Other Advanced Therapies
Maryia Zhdanava, Timothy P. Fitzgerald, Porpong Boonmak, Dominic Pilon, Samuel Schwartzbein, Béatrice Libchaber, Steven Feldman
On-Label Persistence in Psoriasis After Switching to Guselkumab or Tumor Necrosis Factor Inhibitors from Other Advanced Therapies
Maryia Zhdanava, Timothy P. Fitzgerald, Porpong Boonmak, Dominic Pilon, Samuel Schwartzbein, Béatrice Libchaber, Steven Feldman
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients With Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
Philip J Mease, Jessica Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F Merola
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients With Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
Philip J Mease, Jessica Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F Merola
SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance at Week 16 Across the Full Range of Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
Linda Stein Gold, Bruce Strober, April W. Armstrong, Theodore Alkousakis, Kim A. Papp, Richard Langley, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Vlada Groysman, Mark G. Lebwohl
Sustained Improvements in Psoriasis Area and Severity Index and in Percent Body Surface Area of Psoriasis With JNJ-77242113 in Patients With Moderate-to-Severe Plaque Psoriasis: Treat-to-Target Analyses in the FRONTIER 1 & 2 Studies
Kim A. Papp, Laura K. Ferris, Andreas Pinter, Phoebe Rich, Ronald B. Vender, Andrew E. Pink, Takayuki Ota, Yaung-Kaung Shen, Shu Li, Amy M. DeLozier, Ya-Wen Yang, Robert Bissonnette
The Power of Imagery in Clinical Medicine: Leveraging Clinical Photos from the VISIBLE Study to Foster Conversations between Clinicians and Patients
Adrian O Rodriguez, Linda Stein Gold, Mona Shahriari, Andrew Alexis, Olivia Choi, Daphne Chan, Theodore Alkousakis, Elizabeth Skobelev, Sancharitha Ramji, Amy McMichael, Susan C Taylor, Seemal R Desai
VISIBLE, Cohort A: Guselkumab Demonstrated Skin Clearance Through Week 48 in Participants With Moderate-to-severe Plaque Psoriasis Across All Skin Tones
Andrew Alexis, Adrian O. Rodriguez, Geeta Yadav, Stephen K. Tyring, Olivia Choi, Theodore Alkousakis, Daphne Chan, Tony Ma, Maxwell Sauder, Javier Alonso-Llamazares, Seemal R. Desai
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.